|
|
Post by therealisaching on Mar 13, 2018 7:14:08 GMT -5
|
|
|
|
Post by sla55 on Mar 13, 2018 7:16:32 GMT -5
investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-stat-study-results-accepted-presentationMannKind Announces STAT Study Results Accepted for Presentation at American Diabetes Association’s 78th Scientific Sessions WESTLAKE VILLAGE, Calif., March 13, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation(Nasdaq:MNKD) focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced that research results from two analyses have been accepted for presentation at the American Diabetes Association’s 78th Scientific Sessions, June 22-26, 2018 in Orlando, Florida: “Improved Postprandial Blood Glucose (PPBG) Excursions with Technosphere Inhaled Insulin Compared with Aspart in T1D Patients – STAT Study” will be an oral presentation “Improved Time-in-Range (TIR) on Continuous Glucose Monitor (CGM)with Technosphere Inhaled Insulin (TI) Compared with Aspart in T1D Patients – STAT Study” will be presented during the scientific poster session The STAT study (STudy comparing insulin Aspart versus Technosphere insulin in patients with type 1 diabetes on multiple daily injections) is the first MannKind study to include and prospectively evaluate the use of continuous glucose monitoring with Afrezza therapy. The dual primary endpoints were assessment of glucose time-in-range as well as post-prandial glucose excursions in the 1-4 hour post-meal period. “We are very pleased with the opportunity to present the STAT Study results at the 78th Scientific Sessions of the American Diabetes Association”, stated Dr. Satish Garg (Barbara Davis Center for Diabetes, University of Colorado Denver), senior author and principal investigator of the collaborative multicenter randomized study. “MannKind welcomes the opportunity to share the results of this collaborative clinical trial and looks forward to pursuing additional analyses to assess the clinical use of Afrezza therapy for mealtime glucose control,” stated David Kendall, MD, Chief Medical Officer of MannKind Corporation. “We believe that the STAT Study results will offer important insights into ways that individuals with diabetes can potentially improve their experience and outcomes by using mealtime inhaled insulin ’in the moment.‘ Our long-term goal is to establish inhaled human insulin as both a useful option and a potential treatment of choice for those individuals with diabetes requiring mealtime glucose control.”
|
|
|
|
Post by uvula on Mar 13, 2018 7:29:21 GMT -5
Until today I didn’t know what STAT stood for. I assumed it was some type of standard drug comparison test.
And since it is not a standard recognized acronym I wonder why they used it in the presentation titles without defining it in the titles.
|
|
|
|
Post by jmkopp on Mar 13, 2018 8:30:38 GMT -5
Does it irritate anyone else that a Company that is financially struggling a bit and having a little trouble gaining better insurance coverage and visibility in the marketplace with their amazing drug that will change the way Diabetes is treated; has to wait an additional 6 months to be able to present their study at the ADA? Wouldn't you think the ADA would want this information to get out to the marketplace as quickly as possible to potentially save more lives rather than force MNKD to wait an additional 6 months just to have the honor of presenting the material at the convention. Does the ADA care more about forcing only presentations that have never been published in an effort to reap the financial benefit of selling more tickets to the event? So, 6 months more of dilution and 6 months more of physicians not getting this knowledge and 6 months longer of low visibility of Afrezza and 6 months longer of weak insurance coverage just to sell a few more tickets to the convention. What am I not understanding about this? Thx.
|
|
|
|
Post by sellhighdrinklow on Mar 13, 2018 8:38:28 GMT -5
Does it irritate anyone else that a Company that is financially struggling a bit and having a little trouble gaining better insurance coverage and visibility in the marketplace with their amazing drug that will change the way Diabetes is treated; has to wait an additional 6 months to be able to present their study at the ADA? Wouldn't you think the ADA would want this information to get out to the marketplace as quickly as possible to potentially save more lives rather than force MNKD to wait an additional 6 months just to have the honor of presenting the material at the convention. Does the ADA care more about forcing only presentations that have never been published in an effort to reap the financial benefit of selling more tickets to the event? So, 6 months more of dilution and 6 months more of physicians not getting this knowledge and 6 months longer of low visibility of Afrezza and 6 months longer of weak insurance coverage just to sell a few more tickets to the convention. What am I not understanding about this? Thx. Agree 100%. The delay is absurd. |
|
|
|
Post by blu2waz on Mar 13, 2018 8:43:07 GMT -5
June 22-26 2018 is not 6 months away
|
|
|
|
Post by boca1girl on Mar 13, 2018 8:46:48 GMT -5
June 22-26 2018 is not 6 months away I think the study was completed in December, wasn’t it? |
|
|
|
Post by tw12 on Mar 13, 2018 8:48:26 GMT -5
jmk: I agree with your questioning. It's an important moral flag to wave, as part of a wholesale readjustment for all of Pharma (BIG and small and trade associations as well) to focus way more closely and wholeheartedly on the immediate needs of patients, to pay much less attention to the games people play for dollars, power and status.
|
|
|
|
Post by dh4mizzou on Mar 13, 2018 8:49:21 GMT -5
jmkopp. It's not their study. It was conducted by the University of Colorado, IIRC. The University has complete control over when, even if, the results will be published.
|
|
|
|
Post by barnstormer on Mar 13, 2018 8:49:55 GMT -5
You understand it completely. ADA is really a self service agency that needs the money from the conference to sustain itself. Doctors won't show up for old news. It is attended however by the type of medical professionals that Mike is targeting. For example Research Hospitals who see a lot of patienfs but don't allow sales reps to pitch them on drugs. ADA provides them a chance to be educated on what is new presented by respected medical professionals for an unvarnished insight into scientific research results. This is why Mike is holding off. I would like to see the results sooner too from an immediate shareprice perspective, but Mike has set the company up to look good to a parter/partners in 2018. STAT at ADA is an important strategic move even though I hate it. While the study was conducted at multiple sites directed by UC MNKD still has input into where and when it is presented.
|
|
|
|
Post by uvula on Mar 13, 2018 8:52:02 GMT -5
Sales reps are almost useless these days. The only way to reach new doctors is to present stuff at medical conferences. I trust Dr. K's judgement on this one.
|
|
|
|
Post by sportsrancho on Mar 13, 2018 8:58:58 GMT -5
Just have to say the reps are working very hard writing pre-authorization letters trying to help patients keep the scripts they have.
|
|
|
|
Post by dg1111 on Mar 13, 2018 9:04:03 GMT -5
Is it safe to assume that the titles of the studies are supported by the results? “Improved Postprandial Blood Glucose (PPBG) Excursions ..." and “Improved Time-in-Range (TIR) ..." are both good conclusions.
Around the 2015 ADA, when we were partnered with Sanofi, sales were gaining a little traction, and there was buzz around ADA. They stock went to about 7 (pre-split). I'm hoping for a similar run up, with sustained growth afterwards.
|
|
|
|
Post by uvula on Mar 13, 2018 9:14:26 GMT -5
Just have to say the reps are working very hard writing pre-authorization letters trying to help patients keep the scripts they have. My apologies to medical sales reps for my clumsy wording. They work hard but the rules make it difficult for them to get access to new doctors. |
|
|
|
Post by jmkopp on Mar 13, 2018 9:58:34 GMT -5
Solid answer. Thanks Barnstormer. I am at least hoping Mike can discuss the results with potential partners with some sort of confidentiality clause to help with negotiations while we wait. It is so frustrating as I have been mentally and financially all in for quite a long time. My ave price is split adjusted 20+ and keeps getting a little worse with every small dilution. If they just get a little traction and visibility, I still believe in great success long term.
|
|
